AnaptysBio

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell AnaptysBio and other ETFs, options, and stocks.

About ANAB

AnaptysBio, Inc. is a clinical stage biotechnology company. engages in the development of antibody product candidates. Its products pipeline include ANB030, ANB030, and Imsidolimab. 

CEO
Daniel R. Faga
CEODaniel R. Faga
Employees
136
Employees136
Headquarters
San Diego, California
HeadquartersSan Diego, California
Founded
2005
Founded2005
Employees
136
Employees136

ANAB Key Statistics

Market cap
933.24M
Market cap933.24M
Price-Earnings ratio
-11.74
Price-Earnings ratio-11.74
Dividend yield
Dividend yield
Average volume
660.78K
Average volume660.78K
High today
$33.91
High today$33.91
Low today
$32.94
Low today$32.94
Open price
$33.33
Open price$33.33
Volume
114.06K
Volume114.06K
52 Week high
$40.96
52 Week high$40.96
52 Week low
$12.21
52 Week low$12.21

Stock Snapshot

As of today, AnaptysBio(ANAB) shares are valued at $33.71. The company's market cap stands at 933.24M, with a P/E ratio of -11.74.

As of 2025-11-13, AnaptysBio(ANAB) stock has fluctuated between $32.94 and $33.91. The current price stands at $33.71, placing the stock +2.3% above today's low and -0.6% off the high.

The AnaptysBio(ANAB)'s current trading volume is 114.06K, compared to an average daily volume of 660.78K.

During the past year, AnaptysBio(ANAB) stock moved between $12.21 at its lowest and $40.96 at its peak.

During the past year, AnaptysBio(ANAB) stock moved between $12.21 at its lowest and $40.96 at its peak.

ANAB News

Benzinga 3d
AnaptysBio To Save $10 Million After Discontinuing Ulcerative Colitis Study

AnaptysBio Inc. (NASDAQ:ANAB) on Monday released data from the Phase 2 trial of rosnilimab for moderate-to-severe ulcerative colitis. ANAB is feeling the press...

AnaptysBio To Save $10 Million After Discontinuing Ulcerative Colitis Study
TipRanks 3d
AnaptysBio: Phase 2 rosnilimab trial did not meet primary, secondary endpoints

AnaptysBio (ANAB) announced that investigational rosnilimab was safe and well tolerated but did not meet the primary endpoint of mean change from baseline in mo...

Simply Wall St 5d
AnaptysBio: Assessing Valuation Following a Strong Run in Share Price

AnaptysBio (ANAB) shares have caught investors' attention as the company’s stock delivered an impressive run recently, gaining nearly 25% over the past month. T...

AnaptysBio: Assessing Valuation Following a Strong Run in Share Price

Analyst ratings

92%

of 12 ratings
Buy
91.7%
Hold
8.3%
Sell
0%

People also own

Based on the portfolios of people who own ANAB. This list is generated using Robinhood data, and it’s not a recommendation.
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer.